Eli Lilly Joins Lawsuit to Defend Drug Patent Against Compounding Pharmacies Amid FDA Regulatory Dispute
Washington, D.C. — Pharmaceutical giant Eli Lilly has entered the legal fray by filing a motion on January 1 to join a lawsuit challenging the U.S. Food and Drug Administration’s (FDA) decision regarding the manufacturing of generic versions of GLP-1 drugs, such as those Lilly markets under the names Mounjaro and Zepbound. The company asserts significant stakes in the ongoing legal battle over whether compounding pharmacies may continue creating generics previously necessitated by drug shortages. The initial lawsuit was launched in October by the Outsourcing Facilities Association and FarmaKeio Custom Compounding, a Texas-based compounding pharmacy. … Read more